Lantheus Medical Imaging, Inc.

331 Treble Cove Road
North Billerica
Massachusetts
01862
United States

Tel: 800-299-3431

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Stock Exchange: NASDAQ

Stock Symbol: LNTH

153 articles about Lantheus Medical Imaging, Inc.

Lantheus Holdings to Host First Quarter 2018 Earnings Conference Call on May 2, 2018 at 4:30 p.m. Eastern Time

4/18/2018

Lantheus Holdings, Inc. announced that it will host a conference call at 4:30 p.m. ET on Wednesday, May 2, 2018, to discuss its financial and operating results for the first quarter of 2018.
Lantheus Holdings to Host Fourth Quarter and Full Year 2017 Earnings Conference Call and Provide 2018 Guidance on February 26, 2018 at 4:30 p.m. Eastern Time

2/13/2018

The Company will also provide guidance for 2018.
Lantheus Holdings Reports 2017 Third Quarter Financial Results; Exceeds Third Quarter and Raises Full-Year 2017 Guidance

11/3/2017

The Company’s worldwide revenues for the third quarter of 2017 totaled $79.9 million.
Lantheus Medical Imaging Announces Public Offering Of 5,200,000 Shares Of Common Stock

9/9/2016
Lantheus Medical Imaging To Host Third Quarter 2015 Earnings Conference Call On November 4, 2015 At 4:30 P.M. Eastern Time

10/22/2015
Massachusetts Debuts Three Biotech IPOs for $235M As Market Roars

6/24/2015
Lantheus Medical Imaging's First Phase 3 Study Of Novel PET Cardiac Imaging Agent Flurpiridaz F 18 Data Show Statistically And Clinically Significant Improvements

5/4/2015
Lantheus Medical Imaging Revives IPO

11/12/2014
Lantheus Medical Imaging Eyes IPO Worth Up To $125 Million

6/27/2014
Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time

11/7/2013
Lantheus Medical Imaging Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease

10/30/2013
Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013

9/10/2013
Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time

8/2/2013
Lantheus Medical Imaging to Present at Wells Fargo Securities 2013 Healthcare Conference

6/12/2013
Lantheus Medical Imaging to Present at Jefferies and Co. 2013 Global Healthcare Conference

5/29/2013
Lantheus Medical Imaging to Host First Quarter 2013 Conference Call on May 14, 2013 at 4:00 P.M. Eastern Time

5/8/2013
Lantheus Medical Imaging to Proceed With Flurpiridaz F 18 Phase 3 Clinical Program Based on Interim Analysis of Data From First Phase 3 Study

5/1/2013
Lantheus Medical Imaging Focuses on Growth, Takes Steps to Reduce Expenses

3/22/2013
Lantheus Medical Imaging Announces Molybdenum-99 Supply Contract With Institute for Radioelements

3/19/2013
Lantheus Medical Imaging Announces Appointment of Cesare Orlandi, M.D., as New Chief Medical Officer

3/6/2013